All In Biotech

Drug Trial Radar · NCT04176653

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

Phase 1b Single Ascending and Multiple Dose First-in-man Study in Adult Patients With Non-transfusion-dependent Beta-thalassaemia or Low Risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN124

Last checked: Nov 19, 2026Latest source record: Apr 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Aug 20, 2019

Primary completion

Sep 30, 2021

Study completion Oct 14, 2021

Sponsor

Lead sponsor
Silence Therapeutics plcIndustry
Sponsor type
Industry
First posted
Nov 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the safety and tolerability of SLN124 for the treatment of non-transfusion-dependent (NTD) β-thalassaemia and low risk myelodysplastic syndrome.

Conditions

  • Non-transfusion-dependent Thalassemia
  • Low Risk Myelodysplastic Syndrome

Interventions

  • SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as PlaceboDrug

    IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. # of participants with all AEs as assessed by CTCAE V4.0 included injection site reaction, will be measured from baseline to post dose follow upTime frame: Up to two months
  2. 12 lead electrocardiogram parameters included PR, QTcF and QTcB will be measured from baseline to post dose follow upTime frame: Up to two months
  3. clinical chemistry, haematology, urinalysis, liver function tests (included ALT, AST, GGT) will be measured from baseline to post dose follow upTime frame: Up to two months
  4. height, weight, blood pressure, heart rate, respiration rate and temperature will be measured from baseline to post dose follow upTime frame: Up to two months

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • MHAT Dr. Nikola Vasiliev AD

    Kyustendil, Bulgaria

  • UMHAT Dr. Georgi Stranski AD

    Pleven, Bulgaria

  • Medical Center COMAC MEDICAL

    Sofia, Bulgaria

  • UMHAT Sv. Ivan Rilski

    Sofia, Bulgaria

  • Hammersmith Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.